Alternative evolutionary paths to bacterial antibiotic resistance cause distinct collateral effects

Molecular Biology and Evolution

Volumn 34, Issue 9, 2017, Pages 2229-2244

  Barbosa, Camilo ^a   Trebosc, Vincent ^b   Kemmer, Christian ^b   Rosenstiel, Philip ^c   Beardmore, Robert ^d   Schulenburg, Hinrich ^a   Jansen, Gunther ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b BIOVERSYS AG   (Switzerland)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

Antibiotic resistance; Collateral sensitivity; Experimental evolution; Pseudomonas aeruginosa; Trade offs

Indexed keywords

CARBENICILLIN; CEFSULODIN; CIPROFLOXACIN; DORIPENEM; GENTAMICIN; IMIPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; STREPTOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; CROSS RESISTANCE; EVOLUTION; MEXZ GENE; NALC GENE; NONHUMAN; PMRB GENE; PSEUDOMONAS AERUGINOSA; SENSITIVITY ANALYSIS; WHOLE GENOME SEQUENCING; BACTERIAL GENOME; BACTERIUM; GENETICS; GENOMICS; MICROBIAL SENSITIVITY TEST; MOLECULAR EVOLUTION; MUTATION; PROCEDURES;

ANTI-BACTERIAL AGENTS; BACTERIA; BIOLOGICAL EVOLUTION; DRUG RESISTANCE, BACTERIAL; EVOLUTION, MOLECULAR; GENOME, BACTERIAL; GENOMICS; MICROBIAL SENSITIVITY TESTS; MUTATION; PSEUDOMONAS AERUGINOSA;

EID: 85037593154     PISSN: 07374038     EISSN: 15371719     Source Type: Journal    
DOI: 10.1093/molbev/msx158     Document Type: Article

References (84)

1. Abyzov A, Urban AE, Snyder M, Gerstein M. 2011. CNVnator: an approach to discover, genotype and characterize typical and atypical CNVs from family and population genome sequencing. Genome Res. 21:974–894.
2. Aires JR, Köhler T, Nikaido H, Plésiat P. 1999. Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother. 43:2624–2628.
3. Amin NE, Giske CG, Jalal S, Keijser B, Kronvall G, Wretlind B. 2005. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. APMIS 113:187–196.
4. Andersson DI, Hughes D. 2010. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol. 8:260–271.
5. Arruda EA, Marinho IS, Boulos M, Sinto SI, Mendes CM, Oplustil CP, Sader H, Levy CE, Levin AS. 1999. Nosocomial infections caused by multiresistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol. 20:620–623.
6. Balasubramanian D, Schneper L, Kumari H, Mathee K. 2013. A dynamic and intricate regulatory network determines Pseudomonas aeruginosa virulence. Nucleic Acids Res. 41:1–20.
7. Barrick JE, Yu DS, Yoon SH, Jeong H, Oh TK, Schneider D, Lenski RE, Kim JF. 2009. Genome evolution and adaptation in a long-term experiment with Escherichia coli. Nature 461:1243–1247.
8. Baym M, Lieberman TD, Kelsic ED, Chait R, Gross R, Yelin I, Kishony R. 2016a. Spatiotemporal microbial evolution on antibiotic landscapes. Science 353:1147–1151.
9. Baym M, Stone LK, Kishony R. 2016b. Multidrug evolutionary strategies to reverse antibiotic resistance. Science 351:aad3292.
10. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, Hall KP, Evers DJ, Barnes CL, Bignell HR, et al. 2008. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456:53–59.
11. Breidenstein EBM, de la Fuente-Nuñez C, Hancock REW. 2011. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 19:419–426.
12. Burrows LL. 2012. Pseudomonas aeruginosa twitching motility: type IV pili in action. Annu Rev Microbiol. 66:493–520.
13. Cabot G, Zamorano L, Moya B, Juan C, Navas A, Blazquez J, Oliver A. 2016. Evolution of Pseudomonas aeruginosa antimicrobial resistance and fitness under low and high mutation rates. Antimicrob Agents Chemother. 60:1767–1778.
14. Cao L, Srikumar R, Poole K. 2004. MexAB-OprM hyperexpression in NalC-type multidrug-resistant Pseudomonas aeruginosa: identification and characterization of the nalC gene encoding a repressor of PA3720-PA3719. Mol Microbiol. 53:1423–1436.
15. Rodrıguez-Rojas A, Oliver A, Blazquez J. 2012. Intrinsic and environmental mutagenesis drive diversification and persistence of Pseudomonas aeruginosa in chronic lung infections. J Infect Dis. 205:121–127.
16. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. 1999. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 43:1379–1382.
17. Chait R, Craney A, Kishony R. 2007. Antibiotic interactions that select against resistance. Nature 446:668–671.
18. Chevereau G, Dravecka M, Batur T, Guvenek A, Ayhan DH, Toprak E, Bollenbach T. 2015. Quantifying the determinants of evolutionary dynamics leading to drug resistance. PLoS Biol. 13:e1002299.
19. Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L, Land SJ, Lu X, Ruden DM. 2012. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6:80–92.
20. Ciofu O, Mandsberg LF, Bjarnsholt T, Wassermann T, Høiby N. 2010. Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants. Microbiology 156:1108–1119.
21. Daigle DM, Cao L, Fraud S, Wilke MS, Pacey A, Klinoski R, Strynadka NC, Dean CR, Poole K. 2007. Protein modulator of multidrug efflux gene expression in Pseudomonas aeruginosa. J Bacteriol. 189:5441–5451.
22. Doyle TB, Hawkins AC, McCarter LL. 2004. The complex flagellar torque generator of Pseudomonas aeruginosa. J. Bacteriol 186:6341–6350.
23. Drenkard E, Ausubel FM. 2002. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 416:740–743.
24. Evgrafov MRD, Gumpert H, Munck C, Thomsen TT, Sommer MOA. 2015. Collateral resistance and sensitivity modulate evolution of high-level resistance to drug combination treatment in Staphylococcus aureus. Mol Biol Evol. 32:1175–1185.
25. Folkesson A, Jelsbak L, Yang L, Johansen HK, Ciofu O, Høiby N, Molin S. 2012. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat Rev Microbiol. 10:841–851.
26. Fuentes-Hernandez A, Plucain J, Gori F, Pena-Miller R, Reding C, Jansen G, Schulenburg H, Gudelj I, Beardmore R. 2015. Using a sequential regimen to eliminate bacteria at sublethal antibiotic dosages. PLoS Biol. 13:e1002104.
27. Gotoh N, Tsujimoto H, Tsuda M, Okamoto K, Nomura A, Wada T, Nakahashi M, Nishino T. 1998. Characterization of the MexC-MexD-OprJ multidrug efflux system in DmexA-mexB-oprM mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 42:1938–1943.
28. Govan JR, Deretic V. 1996. Microbial pathogenesis in cystic fibrosis: mu-coid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev. 60:539–574.
29. Hancock REW, Speert DP. 2000. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Resist Updat. 3:247–255.
30. Hauser AR. 2009. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat Rev Microbiol. 7:654–665.
31. Hegreness M, Shoresh N, Damian D, Hartl D, Kishony R. 2008. Accelerated evolution of resistance in multidrug environments. Proc Natl Acad Sci U S A. 105:13977–13981.
32. Hoch JA. 2000. Two-component and phosphorelay signal transduction. Curr Opin Microbiol. 3:165–170.
33. Imamovic L, Sommer MOA. 2013. Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. Sci Transl Med. 5:204ra132–204ra132.
34. Jansen G, Crummenerl LL, Gilbert F, Mohr T, Pfefferkorn R, Th€anert R, Rosenstiel P, Schulenburg H. 2015. Evolutionary transition from pathogenicity to commensalism: global regulator mutations mediate fitness gains through virulence attenuation. Mol Biol Evol. 32:2883–2896.
35. Jeannot K, Elsen S, Köhler T, Attree I, van Delden C, Plésiat P. 2008. Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. Antimicrob Agents Chemother. 52:2455–2462.
36. Jiang H, Lei R, Ding S-W, Zhu S. 2014. Skewer: a fast and accurate adapter trimmer for next-generation sequencing paired-end reads. BMC Bioinformatics 15:182.
37. Jimenez PN, Koch G, Thompson JA, Xavier KB, Cool RH, Quax WJ. 2012. The multiple signaling systems regulating virulence in Pseudomonas aeruginosa. Microbiol Mol Biol Rev. 76:46–65.
38. Kang C-I, Kim S-H, Kim H-B, Park S-W, Choe Y-J, Oh M, Kim E-C, Choe KW. 2003. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis. 37:745–751.
39. Kim S, Lieberman TD, Kishony R. 2014. Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance. Proc Natl Acad Sci U S A. 111:14494–14499.
40. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis ER, Ding L, Wilson RK. 2012. VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. Available from: http://genome.cshlp.org/content/early/2012/02/02/gr.129684.111
41. Korotkov KV, Sandkvist M, Hol WGJ. 2012. The type II secretion system: biogenesis, molecular architecture and mechanism. Nat Rev Microbiol. 10:336–351.
42. Kugelberg E, Löfmark S, Wretlind B, Andersson DI. 2005. Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa. J Antimicrob Chemother. 55:22–30.
43. Kussell E. 2013. Evolution in microbes. Annu Rev Biophys. 42:493–514.
44. Lazar V, Nagy I, Spohn R, Csörg}o B, Györkei A, Nyerges A, Horvath B, Vörös A, Busa-Fekete R, Hrtyan M, et al. 2014. Genome-wide analysis captures the determinants of the antibiotic cross-resistance interaction network. Nat Commun. 5:4352.
45. Lazar V, Singh GP, Spohn R, Nagy I, Horvath B, Hrtyan M, Busa-Fekete R, Bogos B, Méhi O, Csörg}o B, et al. 2013. Bacterial evolution of antibiotic hypersensitivity. Mol Syst Biol. 9:700. [Internet] Available from: http://msb.embopress.org/content/9/1/700.
46. Lenski RE, Rose MR, Simpson SC, Tadler SC. 1991. Long-term experimental evolution in Escherichia coli. I. Adaptation and divergence during 2,000 generations. Am Nat. 138:1315–1341.
47. Levin-Reisman I, Ronin I, Gefen O, Braniss I, Shoresh N, Balaban NQ. 2017. Antibiotic tolerance facilitates the evolution of resistance. Science 355:826–830.
48. Li H, Durbin R. 2010. Fast and accurate long-read alignment with Burrows–Wheeler transform. Bioinformatics 26:589–595.
49. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, Subgroup 1000 Genome Project Data Processing. 2009. The sequence alignment/map format and SAMtools. Bioinformatics 25:2078–2079.
50. Li X-Z, Zhang L, Poole K. 2000. Interplay between the MexA-MexB-OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa. J Antimicrob Chemother. 45:433–436.
51. Livermore DM. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 34:634–640.
52. Loper JE, Hassan KA, Mavrodi DV, Ii EWD, Lim CK, Shaffer BT, Elbourne LDH, Stockwell VO, Hartney SL, Breakwell K, et al. 2012. Comparative genomics of plant-associated Pseudomonas spp.: insights into diversity and inheritance of traits involved in multitrophic interactions. PLoS Genet. 8:e1002784.
53. Ma L, Conover M, Lu H, Parsek MR, Bayles K, Wozniak DJ. 2009. Assembly and development of the Pseudomonas aeruginosa biofilm matrix. PLoS Pathog. 5:e1000354.
54. Macfarlane ELA, Kwasnicka A, Hancock REW. 2000. Role of Pseudomonas aeruginosa PhoP-PhoQ in resistance to antimicrobial cationic peptides and aminoglycosides. Microbiology 146:2543–2554.
55. Maseda H, Yoneyama H, Nakae T. 2000. Assignment of the substrate-selective subunits of the MexEF-OprN multidrug efflux pump of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 44:658–664.
56. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. 2000. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 44:3322–3327.
57. McPhee JB, Lewenza S, Hancock REW. 2003. Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa. Mol Microbiol. 50:205–217.
58. Melnyk AH, Wong A, Kassen R. 2015. The fitness costs of antibiotic resistance mutations. Evol Appl. 8:273–283.
59. Michel J-B, Yeh PJ, Chait R, Moellering RC, Kishony R. 2008. Drug interactions modulate the potential for evolution of resistance. Proc Natl Acad Sci U S A. 105:14918–14923.
60. Miller C, Thomsen LE, Gaggero C, Mosseri R, Ingmer H, Cohen SN. 2004. SOS Response induction by ß-lactams and bacterial defense against antibiotic lethality. Science 305:1629–1631.
61. Montanari S, Oliver A, Salerno P, Mena A, Bertoni G, Tümmler B, Cariani L, Conese M, Döring G, Bragonzi A. 2007. Biological cost of hyper-mutation in Pseudomonas aeruginosa strains from patients with cystic fibrosis. Microbiology 153:1445–1454.
62. Munck C, Gumpert HK, Wallin AIN, Wang HH, Sommer MOA. 2014. Prediction of resistance development against drug combinations by collateral responses to component drugs. Sci Transl Med. 6:262ra156–262ra156.
63. Murtagh F, Legendre P. 2014. Ward’s hierarchical agglomerative clustering method: which algorithms implement ward’s criterion? J Classif. 31:274–295.
64. Nikel PI, Martınez-Garcıa E, de Lorenzo V. 2014. Biotechnological domestication of pseudomonads using synthetic biology. Nat Rev Microbiol. 12:368–379.
65. Oliver A, Baquero F, Blazquez J. 2002. The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Mol Microbiol. 43:1641–1650.
66. Overhage J, Bains M, Brazas MD, Hancock REW. 2008. Swarming of Pseudomonas aeruginosa is a complex adaptation leading to increased production of virulence factors and antibiotic resistance. J Bacteriol. 190:2671–2679.
67. Oz T, Guvenek A, Yildiz S, Karaboga E, Tamer YT, Mumcuyan N, Ozan VB, Senturk GH, Cokol M, Yeh P, et al. 2014. Strength of selection pressure is an important parameter contributing to the complexity of antibiotic resistance evolution. Mol Biol Evol. 31:2387–2401.
68. Pal C, Papp B, Lazar V. 2015. Collateral sensitivity of antibiotic-resistant microbes. Trends Microbiol. 23:401–407.
69. Pena-Miller R, Laehnemann D, Jansen G, Fuentes-Hernandez A, Rosenstiel P, Schulenburg H, Beardmore R. 2013. When the most potent combination of antibiotics selects for the greatest bacterial load: the Smile-Frown transition. PLoS Biol. 11:e1001540.
70. Piddock LJV. 2006. Multidrug-resistance efflux pumps? not just for resistance. Nat Rev Microbiol. 4:629–636.
71. Poole K. 2001. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J Mol Microbiol Biotechnol. 3:255–264.
72. R Core Team .R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. Available from: https://www.R-project.org/.
73. Ramos JL, Martınez-Bueno M, Molina-Henares AJ, Teran W, Watanabe K, Zhang X, Gallegos MT, Brennan R, Tobes R. 2005. The TetR family of transcriptional repressors. Microbiol Mol Biol Rev. 69:326–356.
74. Rodrigue A, Quentin Y, Lazdunski A, Méjean V, Foglino M. 2000. Cell signalling by oligosaccharides. Two-component systems in Pseudomonas aeruginosa: why so many? Trends Microbiol. 8:498–504.
75. Robinson VL, Buckler DR, Stock AM. 2000. A tale of two components: a novel kinase and a regulatory switch. Nat Struct Mol Biol. 7:626–633.
76. Roemhild R, Barbosa C, Beardmore RE, Jansen G, Schulenburg H. 2015. Temporal variation in antibiotic environments slows down resistance evolution in pathogenic Pseudomonas aeruginosa. Evol Appl. 8:945–955.
77. Szybalski W, Bryson V. 1952. Genetic studies on microbial cross resistance to toxic agents I. J Bacteriol. 64:489–499.
78. Tenaillon O, Barrick JE, Ribeck N, Deatherage DE, Blanchard JL, Dasgupta A, Wu GC, Wielgoss S, Cruveiller S, Médigue C, et al. 2016. Tempo and mode of genome evolution in a 50,000-generation experiment. Nature 536:165–170.
79. Toprak E, Veres A, Michel J-B, Chait R, Hartl DL, Kishony R. 2012. Evolutionary paths to antibiotic resistance under dynamically sustained drug selection. Nat Genet. 44:101–105.
80. Trebosc V, Gartenmann S, Royet K, Manfredi P, Tötzl M, Schellhorn B, Pieren M, Tigges M, Lociuro S, Sennhenn PC, et al. 2016. A novel genome-editing platform for drug-resistant Acinetobacter bauman-nii reveals an ader-unrelated tigecycline resistance mechanism. Antimicrob Agents Chemother. 60:7263–7271.
81. Tsutsumi Y, Tomita H, Tanimoto K. 2013. Identification of novel genes responsible for overexpression of ampC in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother. 57:5987–5993.
82. Wei Z, Wang W, Hu P, Lyon GJ, Hakonarson H. 2011. SNVer: a statistical tool for variant calling in analysis of pooled or individual next-generation sequencing data. Nucleic Acids Res. 39:e132–e132.
83. Westbrock-Wadman S, Sherman DR, Hickey MJ, Coulter SN, Zhu YQ, Warrener P, Nguyen LY, Shawar RM, Folger KR, Stover CK. 1999. Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability. Antimicrob Agents Chemother. 43:2975–2983.
84. Ye K, Schulz MH, Long Q, Apweiler R, Ning Z. 2009. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25:2865–2871.